Tesofensine

Nupenta, TesometNot a peptide · small moleculeMetabolic/Weight

Evidence grade

BRegion-specific approval (not US FDA)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeMetabolic / Weight loss

MechanismTriple monoamine reuptake inhibitor, raising dopamine, serotonin and noradrenaline. Not a peptide and not an incretin — a centrally acting appetite suppressant.

EffectsPhase 2 mean weight loss of 4.5% at 0.25 mg/day and 9.2% at 0.5 mg/day.

DosingNot FDA-approved. Approved in Mexico since 2023 as Nupenta (monotherapy) and Tesomet (with metoprolol). Phase 3 planning used 0.25 and 0.5 mg/day orally.

Bottom lineReal weight-loss data and a real cardiovascular liability, which is why it is sold with a beta blocker where it is approved at all.

Batches on filenone

No tested batches on file.

Read with

The library records no pairings for this entry.

Cautions & interactions

Monoamine reuptake inhibition raises heart rate and blood pressure, which is why the Mexican combination product pairs it with a beta blocker. Not approved in the US.

Serious interaction risk with MAO inhibitors, SSRIs, SNRIs and other serotonergic or sympathomimetic agents. Coadministration with monoamine-active drugs needs specialist oversight.

CV 1 of 5 — Raises heart rate and blood pressure through monoamine reuptake inhibition. The approved Mexican combination adds metoprolol specifically to offset this. Treat as a cardiovascular liability, not a neutral agent.